Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Waldenstrom Macroglobulinemia × Rituximab × Clear all

Phase

Phase 2 54 Phase 1 16 Phase 1/2 15 Phase 3 3 Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Non-Hodgkin 4 Lymphoma, Follicular 3 Lymphoma 3 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia 1

Interventions

Cyclophosphamide 2 ibrutinib 1 fludarabine phosphate 1 Whole-Body Irradiation 1 Thiotepa 1 Rituximab 1 Melphalan 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Busulfan 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04061512 2024-05-10

RAINBOW

University College, London

Phase 2/3 Recruiting

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡